Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Elicio Therapeutics, Inc. (ELTX : NSDQ)

• Company Description    Elicio Therapeutics is a privately-held clinical-stage biotechnology company. It involved in developing a pipeline of novel immunotherapies for the treatment of cancer and other diseases. Elicio Therapeutics, formerly known as Angion Biomedica Corp, is based in BOSTON. Number of Employees: 32

• Price / Volume Information    Yesterday's Closing Price: $8.55 Daily Weekly Monthly 20 Day Moving Average: 142,800 shares Shares Outstanding: 17.49 (millions) Market Capitalization: $149.54 (millions) Beta: 1.19 52 Week High: $12.62 52 Week Low: $4.60 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 3.64% 5.21% 12 Week 1.18% -2.27% Year To Date 7.41% 7.56%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 451 D Street 5th Floor - Boston,MA 02210 USA ph: 857-209-0050 fax: - ir@elicio.com http://www.elicio.com

• General Corporate Information    Officers Robert Connelly - Chief Executive Officer and President Jay Venkatesan - Director Julian Adams - Director Carol Ashe - Director Karen Wilson - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 28657F103 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 09/01/25 Next Expected EPS Date: 03/30/26 Share - Related Items Shares Outstanding: 17.49 Most Recent Split Date: 6.00 (0.10:1) Beta: 1.19 Market Capitalization: $149.54 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.48 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-1.72 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 03/30/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 36.61 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 56.83% vs. Previous Quarter: 9.09% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 12/31/25 - - 09/30/25 - -5,657.87 06/30/25 - - ROA 12/31/25 - - 09/30/25 - -160.71 06/30/25 - -175.83 Current Ratio 12/31/25 - - 09/30/25 - 3.29 06/30/25 - 2.28 Quick Ratio 12/31/25 - - 09/30/25 - 3.29 06/30/25 - 2.28 Operating Margin 12/31/25 - - 09/30/25 - - 06/30/25 - - Net Margin 12/31/25 - - 09/30/25 - - 06/30/25 - - Pre-Tax Margin 12/31/25 - - 09/30/25 - - 06/30/25 - - Book Value 12/31/25 - - 09/30/25 - 0.23 06/30/25 - 0.11 Inventory Turnover 12/31/25 - - 09/30/25 - - 06/30/25 - - Debt-to-Equity 12/31/25 - - 09/30/25 - 2.55 06/30/25 - 5.09 Debt-to-Capital 12/31/25 - - 09/30/25 - 71.81 06/30/25 - 83.58

Powered by Zacks Investment Research ©